Repligen (NASDAQ:RGEN) Shares Gap Up to $129.58

Repligen Co. (NASDAQ:RGEN) gapped up prior to trading on Tuesday . The stock had previously closed at $129.58, but opened at $140.26. Repligen shares last traded at $134.70, with a volume of 175,195 shares trading hands.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of research reports. Guggenheim initiated coverage on shares of Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $194.00.

Repligen Stock Performance

The company has a market capitalization of $7.49 billion, a PE ratio of 518.34, a PEG ratio of 4.14 and a beta of 0.96. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The firm’s 50-day simple moving average is $138.55 and its 200-day simple moving average is $167.64.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. Repligen’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period last year, the firm earned $0.64 earnings per share. On average, research analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Martin D. Madaus acquired 1,615 shares of Repligen stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the purchase, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Martin D. Madaus acquired 1,615 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the acquisition, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by company insiders.

Institutional Trading of Repligen

Several large investors have recently made changes to their positions in the business. Lecap Asset Management Ltd. purchased a new stake in shares of Repligen in the 2nd quarter valued at $1,643,000. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Repligen in the 2nd quarter valued at $273,000. Fifth Third Bancorp boosted its holdings in shares of Repligen by 6.4% in the 2nd quarter. Fifth Third Bancorp now owns 3,096 shares of the biotechnology company’s stock valued at $390,000 after acquiring an additional 187 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Repligen in the 2nd quarter valued at $2,918,000. Finally, Raymond James & Associates boosted its holdings in Repligen by 3.7% during the second quarter. Raymond James & Associates now owns 55,119 shares of the biotechnology company’s stock worth $6,948,000 after buying an additional 1,951 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.